Cite
MLA Citation
Srdan Verstovsek et al.. “Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies.” Journal of hematology & oncology, vol. 9, no. 1, 2016, pp. 1–12. http://access.bl.uk/ark:/81055/vdc_100080954858.0x000081